DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Motzer RJ. et al.
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Lancet Oncol 2013;
14: 552-562
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.